Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Reynolds

Showing results (971-980 of 1,084) with videos related to

Pageof 109
Sort By:
Journal of the American Heart Association|November 26, 2025
Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With CancerGiselle Alexandra Suero-Abreu, Zsofia D Drobni, Carlos A Gongora, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|June 21, 2021
Defining Clinical Public HealthBernard Choi, Barry Pakes, Rose Bilotta, et al.
Human Molecular Genetics|November 11, 2025
Tuberous sclerosis complex-associated renal cell carcinoma, an underappreciated form of familial renal cancer, is characterized by activation of the TFEB/TFE3 pathwayChristopher J Ricketts, Cathy D Vocke, Martin Lang, et al.
JAMA Dermatology|January 12, 2022
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 TherapyKimberly Tang, Jayhyun Seo, Bruce C Tiu, et al.
Nature Methods|August 4, 2022
PROBER identifies proteins associated with programmable sequence-specific DNA in living cellsSmarajit Mondal, Muthukumar Ramanathan, Weili Miao, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2025
Effect of systemic glucocorticoid immunosuppression timing, dose, and duration on overall survival among immune checkpoint inhibitor recipients: a retrospective multicohort studyGuihong Wan, Nga Nguyen, Charles Lu, et al.
International Journal for Equity in Health|December 13, 2016
Hot topics, urgent priorities, and ensuring success for racial/ethnic minority young investigators in academic pediatricsGlenn Flores, Fernando S Mendoza, Elena Fuentes-Afflick, et al.
Kidney International Reports|October 26, 2020
Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 InhibitorsHarish Seethapathy, Sophia Zhao, Ian A Strohbehn, et al.
Journal for Immunotherapy of Cancer|July 3, 2021
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world dataKerry L Reynolds, Shaily Arora, Ravikumar Komandur Elayavilli, et al.
BMC Cancer|May 25, 2011
The association of quality of life with potentially remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancerJames F Grutsch, Carol Ferrans, Patricia A Wood, et al.
Pageof 109

Showing results (971-980 of 1,084) with videos related to

Sort By:
Pageof 109
Journal of the American Heart Association|November 26, 2025
Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With CancerGiselle Alexandra Suero-Abreu, Zsofia D Drobni, Carlos A Gongora, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|June 21, 2021
Defining Clinical Public HealthBernard Choi, Barry Pakes, Rose Bilotta, et al.
Human Molecular Genetics|November 11, 2025
Tuberous sclerosis complex-associated renal cell carcinoma, an underappreciated form of familial renal cancer, is characterized by activation of the TFEB/TFE3 pathwayChristopher J Ricketts, Cathy D Vocke, Martin Lang, et al.
JAMA Dermatology|January 12, 2022
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 TherapyKimberly Tang, Jayhyun Seo, Bruce C Tiu, et al.
Nature Methods|August 4, 2022
PROBER identifies proteins associated with programmable sequence-specific DNA in living cellsSmarajit Mondal, Muthukumar Ramanathan, Weili Miao, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2025
Effect of systemic glucocorticoid immunosuppression timing, dose, and duration on overall survival among immune checkpoint inhibitor recipients: a retrospective multicohort studyGuihong Wan, Nga Nguyen, Charles Lu, et al.
International Journal for Equity in Health|December 13, 2016
Hot topics, urgent priorities, and ensuring success for racial/ethnic minority young investigators in academic pediatricsGlenn Flores, Fernando S Mendoza, Elena Fuentes-Afflick, et al.
Kidney International Reports|October 26, 2020
Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 InhibitorsHarish Seethapathy, Sophia Zhao, Ian A Strohbehn, et al.
Journal for Immunotherapy of Cancer|July 3, 2021
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world dataKerry L Reynolds, Shaily Arora, Ravikumar Komandur Elayavilli, et al.
BMC Cancer|May 25, 2011
The association of quality of life with potentially remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancerJames F Grutsch, Carol Ferrans, Patricia A Wood, et al.
Pageof 109